38206930|t|A randomized, double-blind, placebo-controlled, multicentre trial on the efficacy of varenicline and bupropion in combination and alone for treatment of alcohol use disorder: Protocol for the COMB study.
38206930|a|BACKGROUND: Alcohol Use Disorder (AUD) is a major cause of premature death, disability and suffering. Available treatments are of modest efficacy and under-prescribed so there is a pressing need for a well-tolerated and effective treatment option for AUD. Dopamine is hypothesized to be involved in the development of alcohol dependence. To challenge the low-dopamine hypothesis of addiction, this randomized, double-blind, placebo-controlled, 13-week, multicentre clinical trial with four parallel arms is designed to evaluate the efficacy of two substances raising dopamine levels, varenicline and bupropion, alone and in combination vs. placebo on alcohol consumption in AUD. Varenicline, a partial agonist at brain nicotinic acetylcholine receptors increases dopamine release, whereas bupropion is a centrally-acting, norepinephrine-dopamine reuptake inhibitor. Varenicline is previously shown to reduce alcohol intake in individuals with AUD. We hypothesize that the effect size of a combination of two drugs affecting dopamine levels in the brain will exceed that of approved AUD therapies. METHODS: Consenting individuals with AUD will be recruited via media advertisements. Those fulfilling the eligibility criteria (N = 380) will be randomized to one of four interventions (n = 95 per arm). Treatment will comprise one week of titration (varenicline 0.5-2 mg; bupropion SR 150-300 mg) plus 12 weeks at steady state. Efficacy will be evaluated using two primary endpoints of alcohol consumption: Heavy Drinking Days and blood levels of phosphatidylethanol. Secondary objectives, exploratory and subgroup analyses will be also performed. The modified Intention-to-Treat and Per Protocol datasets will be evaluated using Analysis of Covariance. Last patient out is estimated to occur in December, 2022. DISCUSSION: The COMB Study aims to evaluate the efficacy of the combination of varenicline and bupropion, two drugs affecting dopamine, on alcohol consumption, and to challenge the low-dopamine hypothesis of addiction. Study Code COMB-BO8, EudraCT 2018-000048-24, Version 3.2, Lido & deBejczy, 2020-06-16; https://clinicaltrials.gov identifier NCT04167306.
38206930	85	96	varenicline	Chemical	MESH:D000068580
38206930	101	110	bupropion	Chemical	MESH:D016642
38206930	153	173	alcohol use disorder	Disease	MESH:D000437
38206930	216	236	Alcohol Use Disorder	Disease	MESH:D000437
38206930	238	241	AUD	Disease	MESH:D000437
38206930	263	278	premature death	Disease	MESH:D003643
38206930	455	458	AUD	Disease	MESH:D000437
38206930	460	468	Dopamine	Chemical	MESH:D004298
38206930	522	540	alcohol dependence	Disease	MESH:D000437
38206930	563	571	dopamine	Chemical	MESH:D004298
38206930	586	595	addiction	Disease	MESH:D019966
38206930	771	779	dopamine	Chemical	MESH:D004298
38206930	788	799	varenicline	Chemical	MESH:D000068580
38206930	804	813	bupropion	Chemical	MESH:D016642
38206930	855	862	alcohol	Chemical	MESH:D000438
38206930	878	881	AUD	Disease	MESH:D000437
38206930	883	894	Varenicline	Chemical	MESH:D000068580
38206930	967	975	dopamine	Chemical	MESH:D004298
38206930	993	1002	bupropion	Chemical	MESH:D016642
38206930	1026	1068	norepinephrine-dopamine reuptake inhibitor	Chemical	-
38206930	1070	1081	Varenicline	Chemical	MESH:D000068580
38206930	1112	1119	alcohol	Chemical	MESH:D000438
38206930	1147	1150	AUD	Disease	MESH:D000437
38206930	1228	1236	dopamine	Chemical	MESH:D004298
38206930	1286	1289	AUD	Disease	MESH:D000437
38206930	1338	1341	AUD	Disease	MESH:D000437
38206930	1551	1562	varenicline	Chemical	MESH:D000068580
38206930	1573	1582	bupropion	Chemical	MESH:D016642
38206930	1687	1694	alcohol	Chemical	MESH:D000438
38206930	1748	1767	phosphatidylethanol	Chemical	MESH:C051521
38206930	1960	1967	patient	Species	9606
38206930	2092	2103	varenicline	Chemical	MESH:D000068580
38206930	2108	2117	bupropion	Chemical	MESH:D016642
38206930	2139	2147	dopamine	Chemical	MESH:D004298
38206930	2152	2159	alcohol	Chemical	MESH:D000438
38206930	2198	2206	dopamine	Chemical	MESH:D004298
38206930	2221	2230	addiction	Disease	MESH:D019966
38206930	Comparison	MESH:D000068580	MESH:D016642
38206930	Association	MESH:D004298	MESH:D000437
38206930	Negative_Correlation	MESH:D000438	MESH:D016642
38206930	Negative_Correlation	MESH:D000068580	MESH:D000438
38206930	Negative_Correlation	MESH:D016642	MESH:D000437
38206930	Positive_Correlation	MESH:D000068580	MESH:D004298
38206930	Negative_Correlation	MESH:D000068580	MESH:D000437

